Eli Lilly and Company

10/23/2024 | Press release | Distributed by Public on 10/23/2024 03:10

Lilly's Kisunla™ (donanemab azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease[...]